P/E ratio for Taisho Pharmaceutical (4581.T)
P/E ratio as of April 2024 (TTM): 35.3
According to Taisho Pharmaceutical 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 35.3246. At the end of 2022 the company had a P/E ratio of 19.0.
P/E ratio history for Taisho Pharmaceutical from 2009 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 19.0 | -64.51% |
| 2021 | 53.5 | 60.17% |
| 2020 | 33.4 | -22.69% |
| 2019 | 43.2 | 177.69% |
| 2018 | 15.6 | -31.72% |
| 2017 | 22.8 | -19.41% |
| 2016 | 28.3 | -4.13% |
| 2015 | 29.5 | 20.36% |
| 2014 | 24.5 | 34.96% |
| 2013 | 18.1 | -4.28% |
| 2012 | 19.0 | 61.03% |
| 2011 | 11.8 | -30.79% |
| 2010 | 17.0 | -26.8% |
| 2009 | 23.2 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.